Obseva’s (OBSV) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Obseva (NASDAQ:OBSV) in a research report report published on Tuesday morning, AnalystRatings.com reports. They currently have a $40.00 target price on the stock.

Several other research firms have also weighed in on OBSV. Zacks Investment Research upgraded Obseva from a sell rating to a hold rating in a research report on Saturday, November 9th. Wedbush restated a buy rating and set a $38.00 price target on shares of Obseva in a research report on Thursday, October 31st. Royal Bank of Canada lifted their price target on Obseva from $18.00 to $19.00 and gave the company an outperform rating in a research report on Tuesday, December 10th. BidaskClub upgraded Obseva from a strong sell rating to a sell rating in a research report on Wednesday, October 30th. Finally, Credit Suisse Group lowered Obseva from an outperform rating to a neutral rating and dropped their price target for the company from $16.00 to $4.00 in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Obseva has an average rating of Hold and a consensus target price of $24.75.

Shares of OBSV traded down $0.37 during mid-day trading on Tuesday, hitting $3.91. 54,900 shares of the company’s stock traded hands, compared to its average volume of 752,357. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.38. Obseva has a 1 year low of $2.37 and a 1 year high of $14.59. The firm has a market capitalization of $194.65 million, a P/E ratio of -1.58 and a beta of 0.50. The business’s 50-day moving average price is $3.71 and its 200-day moving average price is $6.88.

Obseva (NASDAQ:OBSV) last posted its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.19. Sell-side analysts anticipate that Obseva will post -2.68 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Morgan Stanley boosted its holdings in Obseva by 358.6% in the second quarter. Morgan Stanley now owns 3,100 shares of the company’s stock worth $35,000 after acquiring an additional 2,424 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Obseva by 263.6% in the second quarter. Cubist Systematic Strategies LLC now owns 3,272 shares of the company’s stock worth $37,000 after acquiring an additional 2,372 shares in the last quarter. Wedbush Securities Inc. boosted its holdings in Obseva by 54.2% in the third quarter. Wedbush Securities Inc. now owns 40,108 shares of the company’s stock worth $334,000 after acquiring an additional 14,100 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Obseva by 7.6% in the second quarter. Renaissance Technologies LLC now owns 79,600 shares of the company’s stock worth $900,000 after acquiring an additional 5,600 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Obseva by 96.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 95,923 shares of the company’s stock worth $366,000 after acquiring an additional 47,012 shares in the last quarter. 63.53% of the stock is currently owned by institutional investors and hedge funds.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

See Also: Hedge Funds Explained

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.